Cargando…
Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking
OBJECTIVE: The main objective is to transfer to clinical practice a new smoking cessation application (“Vive sin Tabaco” a) in all health centers of the public Basque Health Service. DESIGN: An implementation study of a smoking cessation program previously validated. After implementation, a retrospe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142851/ https://www.ncbi.nlm.nih.gov/pubmed/35636019 http://dx.doi.org/10.1016/j.aprim.2022.102363 |
_version_ | 1784715662075101184 |
---|---|
author | Cobos-Campos, Raquel Apiñaniz, Antxon Sáez de Lafuente, Arantza Parraza, Naiara |
author_facet | Cobos-Campos, Raquel Apiñaniz, Antxon Sáez de Lafuente, Arantza Parraza, Naiara |
author_sort | Cobos-Campos, Raquel |
collection | PubMed |
description | OBJECTIVE: The main objective is to transfer to clinical practice a new smoking cessation application (“Vive sin Tabaco” a) in all health centers of the public Basque Health Service. DESIGN: An implementation study of a smoking cessation program previously validated. After implementation, a retrospective study has been carried out to evaluate its use under normal conditions. SITE: The process of transfer to clinical practice has been held in several phases; first a pilotage in four health centers of Alava and subsequently, when all reported incidents were resolved, it was extended to all health centers of the Basque Health Service. INTERVENTION AND MAIN MEASUREMENT: Development of “Vive sin Tabaco”; a corporate tool for smoking cessation, and its transfer to clinical practice. All interested health care workers received training on how to use the application. User manuals for both patients and professionals were developed. Smoking cessation rates at 12 months during implementation were also collected. RESULTS: The percentage of patients of post pilot phase who quit smoking at 12 months was 14.1%. CONCLUSIONS: The conception of “Vive sin tabaco” as a corporate tool for smoking cessation, available in all health centers of Basque Health Service, has been long and arduous, and has required the participation of health professionals and patients as end-users in order to obtain a tool that adapts to their expectations and guarantees greater usability and satisfaction. This application is being effective as an adjuvant tool to health advice. |
format | Online Article Text |
id | pubmed-9142851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91428512022-05-29 Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking Cobos-Campos, Raquel Apiñaniz, Antxon Sáez de Lafuente, Arantza Parraza, Naiara Aten Primaria Original Article OBJECTIVE: The main objective is to transfer to clinical practice a new smoking cessation application (“Vive sin Tabaco” a) in all health centers of the public Basque Health Service. DESIGN: An implementation study of a smoking cessation program previously validated. After implementation, a retrospective study has been carried out to evaluate its use under normal conditions. SITE: The process of transfer to clinical practice has been held in several phases; first a pilotage in four health centers of Alava and subsequently, when all reported incidents were resolved, it was extended to all health centers of the Basque Health Service. INTERVENTION AND MAIN MEASUREMENT: Development of “Vive sin Tabaco”; a corporate tool for smoking cessation, and its transfer to clinical practice. All interested health care workers received training on how to use the application. User manuals for both patients and professionals were developed. Smoking cessation rates at 12 months during implementation were also collected. RESULTS: The percentage of patients of post pilot phase who quit smoking at 12 months was 14.1%. CONCLUSIONS: The conception of “Vive sin tabaco” as a corporate tool for smoking cessation, available in all health centers of Basque Health Service, has been long and arduous, and has required the participation of health professionals and patients as end-users in order to obtain a tool that adapts to their expectations and guarantees greater usability and satisfaction. This application is being effective as an adjuvant tool to health advice. Elsevier 2022-07 2022-05-26 /pmc/articles/PMC9142851/ /pubmed/35636019 http://dx.doi.org/10.1016/j.aprim.2022.102363 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Cobos-Campos, Raquel Apiñaniz, Antxon Sáez de Lafuente, Arantza Parraza, Naiara Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking |
title | Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking |
title_full | Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking |
title_fullStr | Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking |
title_full_unstemmed | Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking |
title_short | Development, validation and transfer to clinical practice of a mobile application for the treatment of smoking |
title_sort | development, validation and transfer to clinical practice of a mobile application for the treatment of smoking |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142851/ https://www.ncbi.nlm.nih.gov/pubmed/35636019 http://dx.doi.org/10.1016/j.aprim.2022.102363 |
work_keys_str_mv | AT coboscamposraquel developmentvalidationandtransfertoclinicalpracticeofamobileapplicationforthetreatmentofsmoking AT apinanizantxon developmentvalidationandtransfertoclinicalpracticeofamobileapplicationforthetreatmentofsmoking AT saezdelafuentearantza developmentvalidationandtransfertoclinicalpracticeofamobileapplicationforthetreatmentofsmoking AT parrazanaiara developmentvalidationandtransfertoclinicalpracticeofamobileapplicationforthetreatmentofsmoking |